KPC Pharmaceuticals,Inc. (SHA:600422)
China · Delayed Price · Currency is CNY 9.24
+0.13 (1.43%)
Jul 29, 2026, 3:00 PM CST
KPC Pharmaceuticals,Inc. Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 6,994 | 9,508 | 11,998 | 15,812 | 10,707 | 8,379 | |
Market Cap Growth | -37.40% | -20.76% | -24.12% | 47.68% | 27.78% | 27.75% |
Enterprise Value | 8,562 | 9,988 | 10,979 | 15,195 | 10,654 | 7,992 |
Last Close Price | 9.06 | 12.56 | 15.53 | 20.16 | 13.53 | 10.34 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 59.58 | 27.17 | 18.51 | 29.24 | 27.94 | 16.50 |
Forward PE | 22.13 | 13.01 | 18.24 | 23.08 | 17.54 | 13.16 |
PS Ratio | 1.21 | 1.45 | 1.43 | 1.88 | 1.29 | 1.01 |
PB Ratio | 1.03 | 1.37 | 1.78 | 1.99 | 2.08 | 1.70 |
P/TBV Ratio | 2.08 | 2.72 | 3.59 | 3.42 | 2.36 | 1.96 |
P/FCF Ratio | - | 47.86 | 16.47 | 24.53 | 70.37 | 542.13 |
P/OCF Ratio | - | 32.87 | 14.85 | 20.96 | 42.17 | 33.30 |
PEG Ratio | - | 0.55 | 0.55 | 1.18 | 1.18 | 1.18 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.48 | 1.52 | 1.31 | 1.80 | 1.29 | 0.97 |
EV/EBITDA Ratio | 73.88 | 23.36 | 11.08 | 17.43 | 14.32 | 14.07 |
EV/EBIT Ratio | - | 37.26 | 13.45 | 21.82 | 18.91 | 19.53 |
EV/FCF Ratio | - | 50.27 | 15.07 | 23.57 | 70.02 | 517.08 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.24 | 0.24 | 0.12 | 0.11 | 0.22 | 0.17 |
Debt / EBITDA Ratio | 13.94 | 3.71 | 0.82 | 0.99 | 1.48 | 1.40 |
Debt / FCF Ratio | - | 8.48 | 1.14 | 1.40 | 7.49 | 53.57 |
Net Debt / Equity Ratio | 0.00 | -0.09 | -0.28 | -0.15 | -0.16 | -0.18 |
Net Debt / EBITDA Ratio | -0.10 | -1.54 | -1.92 | -1.38 | -1.13 | -1.60 |
Net Debt / FCF Ratio | 0.03 | -3.31 | -2.61 | -1.86 | -5.51 | -58.67 |
Asset Turnover | 0.49 | 0.54 | 0.68 | 0.78 | 0.90 | 0.97 |
Inventory Turnover | 2.37 | 2.78 | 2.88 | 2.63 | 2.72 | 2.70 |
Quick Ratio | 1.55 | 1.58 | 1.22 | 1.59 | 1.21 | 1.12 |
Current Ratio | 2.09 | 2.02 | 1.56 | 2.11 | 1.74 | 1.77 |
Return on Equity (ROE) | 2.35% | 6.12% | 10.22% | 9.81% | 7.65% | 10.76% |
Return on Assets (ROA) | -0.34% | 1.37% | 4.10% | 4.01% | 3.84% | 2.99% |
Return on Invested Capital (ROIC) | -0.87% | 4.26% | 11.32% | 10.30% | 10.92% | 8.71% |
Return on Capital Employed (ROCE) | -0.80% | 3.40% | 11.50% | 8.30% | 10.20% | 7.60% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 1.68% | 3.68% | 5.40% | 3.42% | 3.58% | 6.06% |
FCF Yield | -4.21% | 2.09% | 6.07% | 4.08% | 1.42% | 0.18% |
Dividend Yield | 1.98% | 1.43% | 1.93% | 0.99% | 1.18% | 2.61% |
Payout Ratio | 237.17% | 80.03% | 26.62% | 27.11% | 60.37% | 40.10% |
Buyback Yield / Dilution | -1.30% | -0.95% | 1.05% | -1.36% | 0.84% | 0.19% |
Total Shareholder Return | 0.70% | 0.48% | 2.98% | -0.37% | 2.02% | 2.80% |